Published On: Sat, Mar 11th, 2017

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Updated Broker Ratings


A number of investment brokers have recently updated their price targets on shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Most recent broker ratings

03/03/2017 – Intercept Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 200 price target on the stock.

02/28/2017 – Intercept Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Citigroup. They now have a USD 240 price target on the stock.

02/24/2017 – Intercept Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 224 price target on the stock.

02/24/2017 – Intercept Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 221 price target on the stock.

02/24/2017 – Intercept Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 110 price target on the stock.

02/13/2017 – Intercept Pharmaceuticals, Inc. had its “underweight” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 60 price target on the stock.

02/10/2017 – Intercept Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 225 price target on the stock.

02/10/2017 – Intercept Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Robert W. Baird. They now have a USD 332 price target on the stock.

02/10/2017 – Intercept Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 200 price target on the stock.

01/20/2017 – Intercept Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Needham & Company.

08/05/2016 – Intercept Pharmaceuticals, Inc. was downgraded to “sell” by analysts at Laidlaw. They now have a USD 105 price target on the stock.

06/01/2016 – Intercept Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 205 price target on the stock.

05/31/2016 – Intercept Pharmaceuticals, Inc. had its “underweight” rating reiterated by analysts at Morgan Stanley. They now have a USD 80 price target on the stock.

05/31/2016 – Intercept Pharmaceuticals, Inc. had its “market outperform” rating reiterated by analysts at JMP Securities. They now have a USD 200 price target on the stock.

05/31/2016 – Intercept Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a USD 128 price target on the stock.

The share price of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) was up +1.72% during the last day of trading, with a day high of 127.69. 251357 shares were traded during the last session.

The stock’s 50 day moving average is 118.30 and its 200 day moving average is 125.82. The stock’s market capitalization is 3.16B. Intercept Pharmaceuticals, Inc. has a 52-week low of 96.63 and a 52-week high of 177.93.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.